(2023)
Durvalumab ± tremelimumab + platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): outcomes by PD-L1 expression and tissue tumor mutational burden.
CLINICAL CANCER RESEARCH.
23,
1689
(2023)
Dosimetric comparison between RapidArc and HyperArc in hippocampal-sparing whole-brain radiotherapy with a simultaneous integrated boost.
MEDICAL DOSIMETRY.
x,
x
(2023)
Efficacy and Safety of Chemotherapy in Elderly Patients with Unresectable Pancreatic Cancer.
JOURNAL OF CLINICAL MEDICINE.
12,
9
(2023)
Predictive Biomarkers for Immune-Checkpoint Inhibitor Treatment Response in Patients with Hepatocellular Carcinoma.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES.
24,
8
(2023)
A Multicenter, Prospective, Observational Study to Evaluate Ethanol-Induced Symptoms in Patients Receiving Docetaxel Chemotherapy.
CANCER RESEARCH AND TREATMENT.
55,
4
(2022)
Changes of Immune Cell Fractions in Patients Treated with Immune Checkpoint Inhibitors.
CANCERS.
14,
14
(2022)
Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report.
JTO Clinical and Research Reports.
3,
6
(2022)
Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report.
JTO Clinical and research reports.
3,
6
(2022)
Modified FOLFIRINOX as a Second-Line Treatment for Patients with Gemcitabine-Failed Advanced Biliary Tract Cancer: A Prospective Multicenter Phase II Study.
CANCERS.
14,
8
(2022)
Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN.
ESMO OPEN.
7,
2
(2022)
Safety and anti-tumor effects of vismodegib in patients with refractory advanced gastric cancer: A single-arm phase-II trial.
JOURNAL OF CANCER.
13,
3
(2021)
Randomized Phase II Study of Axitinib versus Observation in Patients with Recurred or Metastatic Adenoid Cystic Carcinoma.
CLINICAL CANCER RESEARCH.
27,
19
(2021)
Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients: A randomised controlled trial (MPACA-3).
EUROPEAN JOURNAL OF CANCER.
157,
2021
(2021)
Real-world efficacy and safety of nab-paclitaxel plus gemcitabine-cisplatin in patients with advanced biliary tract cancers: a multicenter retrospective analysis.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY.
13,
1
(2021)
A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin postoperative chemoradiation with S-1 oxaliplatin in patients with node-positive gastric cancer after D2 resection the ARTIST 2 trial.
ANNALS OF ONCOLOGY.
32,
3
(2021)
Relationship between heavy metal exposure and type 2 diabetes: a large-scale retrospective cohort study using occupational health examinations.
BMJ OPEN.
11,
3
(2021)
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
LANCET ONCOLOGY.
22,
1
(2020)
Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study.
LUNG CANCER.
149,
1
(2020)
A Randomized Controlled Trial of Epidermal Growth Factor Ointment for Treating Epidermal Growth Factor Receptor Inhibitor-Induced Skin Toxicities.
ONCOLOGIST.
25,
1
Conference Paper
(2020)
Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN.
ESMO ASIA.
SINGAPORE
(2016)
A study on the correlation between body composition and durability of chemotherapy; A prospective cohort study.
ESMO ASIA 2016.
SINGAPORE
(2016)
Chemotherapy versus best supportive care in patients with advanced biliary tract carcinoma: A propensity score-matched analysis..
2016 Gastrointestinal Cancers Symposium.
UNITED STATES
(2014)
Natural history of untreated patients who had metastatic biliary tract cancer (BTC) with good performance status (PS)..
2014 ASCO annual meeting.
UNITED STATES